Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?

The role played by glycoprotein (GP) IIb/IIIa inhibitors has continuously evolved from the initial introduction in mid 90 s until the most recent guidelines for treating acute coronary syndromes, and competed with a wider use of ADP inhibitors and novel anticoagulant drugs, to the extent that they s...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannetta, Loredana, Puddu, Paolo Emilio, Cuturello, Domenico, Saladini, Angela, Pellicano, Mariano, Schiariti, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358181/
https://www.ncbi.nlm.nih.gov/pubmed/28348696
http://dx.doi.org/10.4021/cr251w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358181/
https://www.ncbi.nlm.nih.gov/pubmed/28348696
http://dx.doi.org/10.4021/cr251w

Ejemplares similares